Cat. No. |
Product Name |
Information |
PC-60208 |
BI 409306
PDE9A inhibitor
|
BI 409306 (SUB 166499) is a potent and selective inhibitor of human and rat PDE9A with IC50 of 65 nM and 168 nM, respectively. |
PC-60206 |
PF-4181366
PDE9A inhibitor
|
PF-4181366 (PF-04181366) is a potent, selective, brain penetrant PDE9A inhibitor with IC50 of 1.8 nM. |
PC-60205 |
PF-04447943
PDE9A inhibitor
|
PF-04447943 (Edelinontrine) is a potent, selective, brain penetrant, orally active PDE9A inhibitor with IC50 of 8.3 nM. |
PC-60093 |
PDE5-IN-6c
|
A novel potent, selective PDE5 inhibitor with IC50 of 0.056 nM for PDE5A1. |
PC-42212 |
R 80123
PDE inhibitor
|
R 80123 is the Z-isomer of R 79595, a highly selective PDE inhibitor, 10-fold more potent than R 79595. |
PC-46014 |
Tadalafil
PDE5 inhibitor
|
Tadalafil (IC-351, IC351) is a potent, selective phosphodiesterase-5 (PDE5) inhibitor (IC50=1 nM). |
PC-46013 |
Nortadalafil
PDE5 inhibitor
|
Nortadalafil (Demethyl Tadalafil) is demethyl tadalafil, a PDE5 inhibitor, currently marketed in pill form for treating erectile dysfunction (ED).. |
PC-42219 |
Roflumilast Impurity E
PDE4 inhibitor
|
Roflumilast Impurity E (3-O-Decyclopropyl Roflumilast) is an impurity of Roflumilast, which is a selective and long-acting inhibitor of PDE-4 with IC50 value of 0.8 nM. |
PC-45952 |
GSK256066 trifluoroacetate
PDE4 inhibitor
|
GSK256066 trifluoroacetate is a potent, selective PDE4 inhibitor with pIC50 of 11.5, 11.3, 11.4, and 11.9 for PDE4B, A, C, and D, respectively. |
PC-42211 |
Revizinone
PDE3 inhibitor
|
Revizinone (R80122) is a potent, selective PDE3 inhibitor with IC50 of 36 nM, displays >20,000-fold selectivity over PDE1. |
PC-42399 |
PDE1-IN-2
PDE1C inhibitor
|
PDE1-IN-2 is a potent, selective PDE1C inhibitor with IC50 of 6 nM, weakly inhibits PDE1B and PDE1A with IC50 of 140 and 164 nM, respectvely. |
PC-45080 |
Rolipram
PDE4 inhibitor
|
Rolipram (SB95952, ZK62711) is a potent, selective inhibitor of phosphodiesterases PDE4 with IC50 of 3 nM, 130 nM and 240 nM for PDE4A, PDE4B, and PDE4D, respectively. |